NICA

Nanologica

Market Cap 43.2M

Nanologica utvecklar produkter baserat på nanoteknik med applikationsområden inom Life Science. Nanologica har under de tre senaste åren tagit fram produkter inom två affärsområden; analytisk kromatografi och drug delivery. Andreas Bhagwani är VD för bolaget sedan år 2011 och har tidigare erfarenhet inom management consulting. Bolaget har 20 anställda i dagsläget och har sitt huvudsäte i Södertälje sedan 2014 då man tog över en forskningsanläggning från AstraZeneca. Aktien är upptagen till handel på Akietorget sedan 2015. Efter ett beslut om att fokusera verksamheten på Life Science delade Nanologica år 2011 ut bolaget Exeger som är marknadsledande inom solceller för inomhusbruk. År 2012 startar bolaget ett utvecklingsprojekt där man ämnar att utveckla en produkt för kromatografiskt bruk. Utvecklingsprojektet resulterade i NLAB Saga som idag används som packningsmaterial inom kromatografi.

+ more
Today
Day High
2.95
2.85
Day Low
2.69
Day Open
2.76
Prev Close
2.60
VWAP
2.9
Volume
202K
Turnover
0.577M
Top Broker
AVA
VWAP
2.8
Avg Volume
35K
Avg Turnover
0.097M
Top Brokers
AVA/NON
VWAP
2.8
Avg Volume
31K
Avg Turnover
0.085M
Top Brokers
AVA/NON
VWAP
2.8
Avg Volume
32K
Avg Turnover
0.090M
Top Brokers
AVA/NON
52 week summary
Price Range
2.6
Last
13.5
Beta
N/A
Market Cap
43.2M
Total Return
-62.8%
Trailing P/E
-0.6
Div Yield
0.0%
Shares Outstanding
16.6M
Next Earnings Date
23 Aug
Stock Exchange
Spotlight Stock Market
5 day chart Go to advanced chart

Identify and measure trend strength in stocks with our Momentum tool to identify potential entry and exit signals. The tool provides a set of the most simple but powerful indicators that identify whether a stock is under sell or buy pressure.

Relative Price Strength
Change 3 Months -40.9%
Change 12 Months -63.8%
Volume Trend
Average Volume 10 vs 60 Days 37.2%
Price VS
52 Week High -78.9%
50 Day Moving Average -14.4%
200 Day moving Average -50.8%

Add article markers

Compare Nanologica to

Prev Close 0 Change 0
High 0 Avg Daily Volume 0
Low 0 Avg Daily Turnover 0
  • Management
  • Andreas Bhagwani, CEO
  • Eva Osterman, CFO
  • Executive board
  • Gisela Sitbon, Chairman of the board
Last updated: 2017-11-22 Source: Redeye
Major Owners Equity Votes
Thomas Eldered 26.0%
26.0%
Rahal Investment AB 11.3%
11.3%
Vega Bianca AB 8.7%
8.7%
Avanza Pension 5.1%
5.1%
Christian Kock 3.9%
3.9%
Nordnet Pensionsförsäkring 3.0%
3.0%
Mikael Lönn 2.8%
2.8%
Paui AB 2.8%
2.8%
3t Invest AB 2.7%
2.7%
Outset Business Advisor AB 2.4%
2.4%
Last updated: 2017-06-01 Source: Redeye/Holdings
Timeframe Transactions Net Shares
Last 12 weeks
1 Purchases
1,262,523
0 Sales
0
Last 24 weeks
1 Purchases
1,262,523
0 Sales
0
Report Date Name Position Transaction Shares Chg Est Value (SEK)

Insider trades are behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Source: Millistream
  •  
  • Profitability
  • ROE
  • ROCE
  • ROIC
  • EBITDA margin
  • EBIT margin
  • Net margin
  • Per share data (SEK)
  • EPS
  • EPS adj
  • Dividend
  • Net debt
  • Total shares
  • Valuation
  • EV (SEKm)
  • P/E
  • P/E diluted
  • P/Sales
  • EV/Sales
  • EV/EBITDA
  • EV/EBIT
  • P/BV
  • Capital structure
  • Equity ratio
  • Debt/equity ratio
  • Net debt(SEKm)
  • Capital employed(SEKm)
  • Capital turnover rate
  • (SEKm)
  • Net sales
  • Total operating costs
  • EBITDA
  • Depreciation
  • Amortization
  • Impairment charges
  • EBIT
  • Share in profits
  • Net financial items
  • Exchange rate dif.
  • Pre-tax profit
  • Tax
  • Net earnings
  • (SEKm)
  • Assets
  • Current assets
  • Cash in banks
  • Receivables
  • Inventories
  • Other current assets
  • Current assets
  • Fixed assets
  • Tangible assets
  • Associated comp.
  • Investments
  • Goodwill
  • Cap. exp. for dev.
  • O intangible rights
  • O non-current assets
  • Total fixed assets
  • Deferred tax assets
  • Total (assets)
  • Liabilities
  • Current liabilities
  • Short-term debt
  • Accounts payable
  • O current liabilities
  • Current liabilities
  • Long-term debt
  • O long-term liabilities
  • Convertibles
  • Total Liabilities
  • Deferred tax liab
  • Provisions
  • Shareholders' equity
  • Minority interest (BS)
  • Minority & equity
  • Total liab & SE
  • (SEKm)
  • Net sales
  • Total operating costs
  • Depreciations total
  • EBIT
  • Taxes on EBIT
  • NOPLAT
  • Depreciation
  • Gross cash flow
  • Change in WC
  • Gross CAPEX
  • Free cash flow
  • 2014
  •  
  • -166.4%
  • -134.0%
  • -321.8%
  • -1,949.6%
  • -2,188.5%
  • -2,233.1%
  •  
  • -4.38
  • -4.38
  • 0.00
  •  
  • 3.4
  •  
  • -6.5
  • 0.0
  • 0.0
  • 0.0
  • -9.8
  • 0.5
  • 0.4
  • 0.0
  •  
  • 41.7%
  • 100.0%
  • -6
  • 2
  • 0.0
  • 2014
  •  
  •  
  • 9
  • 1
  • 0
  • 2
  • 11
  •  
  • 1
  • 0
  • 0
  • 0
  • 0
  • 7
  • 0
  • 8
  • 0
  • 20
  •  
  •  
  • 0
  • 8
  • 0
  • 8
  • 2
  • 0
  • 0
  • 11
  • 0
  • 1
  • 8
  • 0
  • 8
  • 20
  • 2014
  • 1
  • -13
  • -2
  • -14
  • 0
  • -14
  • 2
  • -13
  • 5
  • -4
  • -12
  • 2014 Q4
  • 1
  • -13
  • -13
  • -2
  • 0
  • 0
  • -14
  • 0
  • 0
  • 0
  • -14
  • 0
  • -15
  • 2015
  •  
  • -81.3%
  • -69.4%
  • -844.8%
  • -401.3%
  • -502.1%
  • -500.3%
  •  
  • -3.91
  • -3.91
  • 0.00
  •  
  • 3.4
  •  
  • 52.6
  • -5.2
  • -5.2
  • 26.2
  • 20.0
  • -5.0
  • -4.0
  • 2.9
  •  
  • 73.7%
  • 3.8%
  • -16
  • 8
  • 0.1
  • 2015
  •  
  •  
  • 19
  • 1
  • 0
  • 2
  • 22
  •  
  • 2
  • 0
  • 0
  • 0
  • 0
  • 9
  • 0
  • 11
  • 0
  • 33
  •  
  •  
  • 0
  • 5
  • 0
  • 6
  • 2
  • 0
  • 0
  • 8
  • 0
  • 0
  • 24
  • 0
  • 24
  • 33
  • 2015
  • 3
  • -13
  • -3
  • -13
  • 0
  • -13
  • 3
  • -11
  • -3
  • -5
  • -19
  • 2015 Q1
  • 2
  • -3
  • -2
  • -1
  • 0
  • 0
  • -2
  • 0
  • 0
  • 0
  • -2
  • 0
  • -2
  • 2015 Q2
  • 1
  • -3
  • -2
  • -1
  • 0
  • 0
  • -3
  • 0
  • 0
  • 0
  • -3
  • 0
  • -3
  • 2015 Q3
  • 0
  • -4
  • -4
  • -1
  • 0
  • 0
  • -4
  • 0
  • 0
  • 0
  • -4
  • 0
  • -4
  • 2015 Q4
  • 0
  • -3
  • -3
  • -1
  • 0
  • 0
  • -4
  • 0
  • 0
  • 0
  • -4
  • 0
  • -4
  • 2016
  •  
  • -103.7%
  • -88.5%
  • -306.5%
  • -998.1%
  • -1,183.7%
  • -1,196.8%
  •  
  • -5.18
  • -5.18
  • 0.00
  •  
  • 4.6
  •  
  • 70.7
  • -3.3
  • -3.3
  • 39.2
  • 35.3
  • -3.5
  • -3.0
  • 3.6
  •  
  • 69.1%
  • 5.6%
  • -8
  • 14
  • 0.1
  • 2016
  •  
  •  
  • 12
  • 1
  • 1
  • 3
  • 18
  •  
  • 2
  • 0
  • 0
  • 0
  • 0
  • 7
  • 0
  • 9
  • 0
  • 28
  •  
  •  
  • 1
  • 5
  • 0
  • 6
  • 4
  • 0
  • 0
  • 9
  • 0
  • 0
  • 22
  • 0
  • 22
  • 32
  • 2016
  • 2
  • -22
  • -4
  • -24
  • 0
  • -24
  • 4
  • -20
  • -3
  • -2
  • -26
  • 2016 Q1
  • 0
  • -5
  • -5
  • -1
  • 0
  • 0
  • -6
  • 0
  • 0
  • 0
  • -6
  • 0
  • -6
  • 2016 Q2
  • 0
  • -6
  • -5
  • -1
  • 0
  • 0
  • -6
  • 0
  • 0
  • 0
  • -7
  • 0
  • -7
  • 2016 Q3
  • 0
  • -6
  • -5
  • -1
  • 0
  • 0
  • -6
  • 0
  • 0
  • 0
  • -6
  • 0
  • -6
  • 2016 Q4
  • 2
  • -6
  • -4
  • -1
  • 0
  • 0
  • -5
  • 0
  • 0
  • 0
  • -6
  • 0
  • -6
  • 2017 E
  • 2017 E
  • 2017 E
  • 2017 Q1 E
  • 2017 Q2 E
  • 2017 Q3 E
  • 2017 Q4 E
  • 2018 E
  • 2018 E
  • 2018 E
  • 2018 Q1 E
  • 2018 Q2 E
  • 2018 Q3 E
  • 2018 Q4 E
  • 2019 E
  • 2019 E
  • 2019 E
  • 2019 Q1 E
  • 2019 Q2 E
  • 2019 Q3 E
  • 2019 Q4 E

Estimated Values are behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Last updated: 2017-11-21 Source: Redeye
Source: Redeye

Presentations, research interviews and videos from our events listed here.

Source: Redeye

When selecting comparable companies, we try to group companies that are in the same or similar sector or subsector. But, more important, have growth, margins and risk characteristics similar to the company being valued.

Community Posts

Be the first to write something about this company in the community.

Create new post